These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 37597219)

  • 1. High Platelet Reactivity Combined with CYP2C19 Genotype in Predicting Outcomes in East Asian Patients Undergoing Percutaneous Coronary Intervention.
    Kim SE; Jeon HS; Go TH; Lee JH; Lee JW; Youn YJ; Kim BK; Joo HJ; Lim DS; Chang K; Park Y; Song YB; Suh JW; Lee SY; Cho JR; Her AY; Kim HS; Kim MH; Shin ES; Gorog DA; Tantry US; Gurbel PA; Jeong YH; Ahn SG;
    Clin Pharmacol Ther; 2023 Nov; 114(5):1104-1115. PubMed ID: 37597219
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Implication of diabetic status on platelet reactivity and clinical outcomes after drug-eluting stent implantation: results from the PTRG-DES consortium.
    Jeon KH; Jeong YH; Chae IH; Kim BK; Joo HJ; Chang K; Park Y; Song YB; Ahn SG; Lee SY; Cho JR; Her AY; Kim HS; Kim MH; Lim DS; Shin ES; Suh JW;
    Cardiovasc Diabetol; 2023 Sep; 22(1):245. PubMed ID: 37679760
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sex Differences in Midterm Prognostic Implications of High Platelet Reactivity After Percutaneous Coronary Intervention With Drug-Eluting Stents in East Asian Patients: Results From the PTRG-DES (Platelet Function and Genotype-Related Long-Term Prognosis in Drug-Eluting Stent-Treated Patients With Coronary Artery Disease) Consortium.
    Kim SJ; Her AY; Jeong YH; Kim BK; Joo HJ; Park Y; Chang K; Song YB; Ahn SG; Suh JW; Lee SY; Cho JR; Kim HS; Kim MH; Lim DS; Shin ES;
    J Am Heart Assoc; 2023 May; 12(9):e027804. PubMed ID: 37119080
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of CYP2C19*2 and *3 loss-of-function alleles on platelet reactivity and adverse clinical events in East Asian acute myocardial infarction survivors treated with clopidogrel and aspirin.
    Jeong YH; Tantry US; Kim IS; Koh JS; Kwon TJ; Park Y; Hwang SJ; Bliden KP; Kwak CH; Hwang JY; Gurbel PA
    Circ Cardiovasc Interv; 2011 Dec; 4(6):585-94. PubMed ID: 22045970
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Platelet Function and Genotype after DES Implantation in East Asian Patients: Rationale and Characteristics of the PTRG-DES Consortium.
    Her AY; Jeong YH; Kim BK; Joo HJ; Chang K; Park Y; Song YB; Ahn SG; Suh JW; Lee SY; Cho JR; Kim HS; Kim MH; Lim DS; Shin ES;
    Yonsei Med J; 2022 May; 63(5):413-421. PubMed ID: 35512743
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CYP2C19 loss-of-function alleles are not associated with clinical outcome of clopidogrel therapy in patients treated with newer-generation drug-eluting stents.
    Choi IJ; Koh YS; Park MW; Her SH; Choi YS; Park CS; Park HJ; Kim PJ; Chung WS; Kim HS; Shin JG; Seung KB; Chang K
    Medicine (Baltimore); 2016 Jun; 95(26):e4049. PubMed ID: 27368038
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interaction analysis between genetic polymorphisms and pharmacodynamic effect in patients treated with adjunctive cilostazol to dual antiplatelet therapy: results of the ACCEL-TRIPLE (Accelerated Platelet Inhibition by Triple Antiplatelet Therapy According to Gene Polymorphism) study.
    Kim IS; Jeong YH; Park Y; Yoon SE; Kwon TJ; Park JR; Hwang SJ; Koh EH; Kwak CH; Hwang JY; Kim S
    Br J Clin Pharmacol; 2012 Apr; 73(4):629-40. PubMed ID: 22007612
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of CYP2C19 genotype with periprocedural myocardial infarction after uneventful stent implantation in Chinese patients receiving clopidogrel pretreatment.
    Wu H; Qian J; Sun A; Wang Q; Ge J
    Circ J; 2012; 76(12):2773-8. PubMed ID: 22971905
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic Implication of Platelet Reactivity According to Left Ventricular Systolic Dysfunction Status in Patients Treated With Drug-Eluting Stent Implantation: Analysis of the PTRG-DES Consortium.
    Han D; Kim SH; Shin DG; Kang MK; Choi S; Lee N; Kim BK; Joo HJ; Chang K; Park Y; Song YB; Ahn SG; Suh JW; Lee SY; Her AY; Jeong YH; Kim HS; Kim MH; Lim DS; Shin ES; Cho JR;
    J Korean Med Sci; 2024 Jan; 39(3):e27. PubMed ID: 38258362
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Impact of CYP2C19 Genotype on Clopidogrel-Based Antiplatelet Therapy After Percutaneous Coronary Intervention.
    Lee SH; Jeong YH; Hong D; Choi KH; Lee JM; Park TK; Yang JH; Hahn JY; Choi SH; Gwon HC; Jeong MH; Kim BK; Joo HJ; Chang K; Park Y; Ahn SG; Suh JW; Lee SY; Cho JR; Her AY; Kim HS; Kim MH; Lim DS; Shin ES; Song YB;
    JACC Cardiovasc Interv; 2023 Apr; 16(7):829-843. PubMed ID: 37045504
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Routine assessment of on-clopidogrel platelet reactivity and gene polymorphisms in predicting clinical outcome following drug-eluting stent implantation in patients with stable coronary artery disease.
    Viviani Anselmi C; Briguori C; Roncarati R; Papa L; Visconti G; Focaccio A; De Micco F; Latronico MV; Pagnotta P; Condorelli G
    JACC Cardiovasc Interv; 2013 Nov; 6(11):1166-75. PubMed ID: 24262617
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic Implication of Platelet Reactivity According to Procedural Complexity After PCI: Subanalysis of PTRG-DES Consortium.
    Jin X; Jeong YH; Lee KM; Yun SC; Kim BK; Joo HJ; Chang K; Park YW; Song YB; Ahn SG; Suh JW; Lee SY; Cho JR; Her AY; Kim HS; Lim DS; Shin ES; Kim MH;
    JACC Asia; 2024 Mar; 4(3):185-198. PubMed ID: 38463677
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of Genotype-Guided Oral P2Y12 Inhibitor Selection vs Conventional Clopidogrel Therapy on Ischemic Outcomes After Percutaneous Coronary Intervention: The TAILOR-PCI Randomized Clinical Trial.
    Pereira NL; Farkouh ME; So D; Lennon R; Geller N; Mathew V; Bell M; Bae JH; Jeong MH; Chavez I; Gordon P; Abbott JD; Cagin C; Baudhuin L; Fu YP; Goodman SG; Hasan A; Iturriaga E; Lerman A; Sidhu M; Tanguay JF; Wang L; Weinshilboum R; Welsh R; Rosenberg Y; Bailey K; Rihal C
    JAMA; 2020 Aug; 324(8):761-771. PubMed ID: 32840598
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical impact of high platelet reactivity in patients with atrial fibrillation and concomitant percutaneous coronary intervention on dual or triple antithrombotic therapy.
    Berteotti M; Gori AM; Giusti B; Fortini A; Grossi G; Ciardetti N; Migliorini A; Lotti E; Valenti R; Di Mario C; Marchionni N; Marcucci R
    J Thromb Thrombolysis; 2023 May; 55(4):667-679. PubMed ID: 36905562
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of Genetic Polymorphisms on Clopidogrel Response and Clinical Outcomes in Patients with Acute Ischemic Stroke CYP2C19 Genotype on Clopidogrel Response.
    Han Y; Lv HH; Liu X; Dong Q; Yang XL; Li SX; Wu S; Jiang JM; Luo Z; Zhu DS; Zhang Y; Zheng Y; Guan YT; Xu JF
    CNS Neurosci Ther; 2015 Sep; 21(9):692-7. PubMed ID: 26177117
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patients carrying CYP2C19 loss of function alleles have a reduced response to clopidogrel therapy and a greater risk of in-stent restenosis after endovascular treatment of lower extremity peripheral arterial disease.
    Guo B; Tan Q; Guo D; Shi Z; Zhang C; Guo W
    J Vasc Surg; 2014 Oct; 60(4):993-1001. PubMed ID: 24877854
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of Implementing CYP2C19 Genotype-Guided Antiplatelet Therapy on P2Y
    Zhang Y; Shi XJ; Peng WX; Han JL; Lin BD; Zhang R; Zhang YN; Yan JL; Wei JJ; Wang YF; Chen SW; Nan N; Fang ZW; Zeng Y; Lin Y
    Front Pharmacol; 2020; 11():582929. PubMed ID: 33551797
    [No Abstract]   [Full Text] [Related]  

  • 18. Paraoxonase-1 activity affects the clopidogrel response in CYP2C19 loss-of-function carriers.
    Nishio R; Shinke T; Otake H; Nakagawa M; Inoue T; Hariki H; Osue T; Taniguchi Y; Iwasaki M; Hiranuma N; Konishi A; Kinutani H; Kuroda M; Hirata K
    Thromb Res; 2013 Nov; 132(5):558-64. PubMed ID: 24080149
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Variability in on-treatment platelet reactivity explained by CYP2C19*2 genotype is modest in clopidogrel pretreated patients undergoing coronary stenting.
    Bouman HJ; Harmsze AM; van Werkum JW; Breet NJ; Bergmeijer TO; Ten Cate H; Hackeng CM; Deneer VH; Ten Berg JM
    Heart; 2011 Aug; 97(15):1239-44. PubMed ID: 21628721
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CYP2C19 loss-of-function alleles predicts clinical outcomes in East Asian patients with acute myocardial infarction undergoing percutaneous coronary intervention and stenting receiving clopidogrel.
    Chen YW; Liao YJ; Chang WC; Hsiao TH; Lin CH; Hsu CY; Liu TJ; Lee WL; Chen YM
    Front Cardiovasc Med; 2022; 9():994184. PubMed ID: 36072879
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.